Lymphedema is mainly identified by progressive soft tissue swelling in impaired lymphatic system.Secondary lymphedema attributed to cancer therapy,parasite infection,and trauma remains a serious global disease.Patient...Lymphedema is mainly identified by progressive soft tissue swelling in impaired lymphatic system.Secondary lymphedema attributed to cancer therapy,parasite infection,and trauma remains a serious global disease.Patients with lymphedema suffer swelling,pain,and fatigue,with the dysfunction of the deformed extremities reducing the quality of life and increasing the risk of infection and lymphangiosarcoma.Adipose-derived stem cells(ADSCs)possess prominent regenerative potential to differentiate into multilineage cells,and produce various lymphangiogenic factors,making ADSC therapy a promising approach for lymphedema.The development of lymphedema consists of local inflammation,the fibrosis of lymphatic vessels,and the deposition of adipose fat.Existing animal models do not mimic the chronic inflammation environment,therefore suitable models are required in further studies.Some signal pathways and molecular mechanisms in physiological and pathological lymphagiogenesis remain unclear.In previous animal and human trials,ADSC therapy reduced edema in varying degrees.A larger number of trials with larger samples and longer follow-up periods are required to verify the efficiency and feasibility of ADSC therapy.ADSCs are of easy availability and immune exemption,making them a candidate for lymphedema treatment.Whether ADSCs enhance malignant characteristics or trigger the malignant change deserves further exploration and study before ADSC therapy can be made widely available.展开更多
基金Supported by The Project of Cadre Institution of Sichuan Province,No.2019-901The Project of Human Resources and Social Security Department Academic and Technical Leader Training Fund in Sichuan,No.2017-A.
文摘Lymphedema is mainly identified by progressive soft tissue swelling in impaired lymphatic system.Secondary lymphedema attributed to cancer therapy,parasite infection,and trauma remains a serious global disease.Patients with lymphedema suffer swelling,pain,and fatigue,with the dysfunction of the deformed extremities reducing the quality of life and increasing the risk of infection and lymphangiosarcoma.Adipose-derived stem cells(ADSCs)possess prominent regenerative potential to differentiate into multilineage cells,and produce various lymphangiogenic factors,making ADSC therapy a promising approach for lymphedema.The development of lymphedema consists of local inflammation,the fibrosis of lymphatic vessels,and the deposition of adipose fat.Existing animal models do not mimic the chronic inflammation environment,therefore suitable models are required in further studies.Some signal pathways and molecular mechanisms in physiological and pathological lymphagiogenesis remain unclear.In previous animal and human trials,ADSC therapy reduced edema in varying degrees.A larger number of trials with larger samples and longer follow-up periods are required to verify the efficiency and feasibility of ADSC therapy.ADSCs are of easy availability and immune exemption,making them a candidate for lymphedema treatment.Whether ADSCs enhance malignant characteristics or trigger the malignant change deserves further exploration and study before ADSC therapy can be made widely available.
